Fresenius Trims China Dialysis Footprint While Betting EUR 54 Million on European Infusion Lines
Published on 09/29/2026 at 17:21 | Editorial boerse-global.de
Fresenius Medical Care is pulling the plug on one of its flagship dialysis machines in China. The standalone kidney-care unit will halt both manufacturing and sales of the 4008A system in the country, and it is simultaneously exiting the Chinese peritoneal dialysis market altogether — a twin retreat that redraws its commercial map in Asia.
The financial hit lands in the third quarter of 2026, when FMC expects one-off charges of roughly EUR 110 million. Impairments, scrapping costs and termination expenses make up the bulk of that figure. Management, however, insists the restructuring will leave future revenue in the China business largely untouched, with no material consequences anticipated for the Care Enablement segment's top line there.
News of the pullback arrived on a Friday, and it follows a turbulent stretch for the dialysis provider's internal operations. On 22 September, FMC disclosed it was investigating a cybersecurity breach involving unauthorized access to a limited number of internal systems. Medical devices, patient care, production and day-to-day business escaped unscathed, according to the company, which brought in outside security specialists and law enforcement to assist the probe.
Fresenius Kabi Widens European Supply Base
While product lines disappear in Asia, the parent group is pouring money into European manufacturing. Fresenius Kabi opened a new infusion-solution production line at its Kutno site in Poland and modernized the production and warehousing infrastructure at Isola della Scala in Italy. Combined, the two projects carry a price tag of EUR 54 million, a sum Fresenius framed as a move to shore up supply security for the healthcare sector.
Should investors sell immediately? Or is it worth buying Fresenius?
The investment announcement came on a Friday, the same day the China decision surfaced.
Helios Gets Staffing and Funding Clarity
Back on 9 September, Fresenius had already set operational changes in motion on the hospital side. Around 1,700 employees at the service companies of Fresenius Health Services are transferring directly to Helios Kliniken GmbH as part of a reorganization. The Health Services division will narrow its focus to serving external clients outside the group going forward.
Planning certainty for the clinic arm arrived mid-September. Fresenius expects a change value of 4.85% for hospital cost reimbursement in 2027, a figure derived from the base wage rate published on 15 September. Barclays analyst Hassan Al-Wakeel flagged the factor as a positive for the hospitals on 16 September, with the investment bank maintaining an "Overweight" rating on Fresenius shares and a price target of EUR 57.50.
Fresenius at a turning point? This analysis reveals what investors need to know now.
Market Response Muted
Trading in the Bad Homburg group's stock has been steady rather than dramatic. The shares closed yesterday with a modest gain of 0.7%, finishing at EUR 46.47, and the paper now sits 4.2% above its 200-day moving average. The combination of the China realignment and predictable reimbursement conditions in the European home market is underpinning the business trajectory, with the share price reflecting what the market reads as a solid operating footing.
Ad
Fresenius Stock: New Analysis - 29 September
Fresh Fresenius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
